Delivery Order SPE2DB25D3012-SPE2DB25FXANB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Valtoco 10 mg nasal sprays, with a ceiling value of $1,129.62. This firm fixed-price delivery order is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Valtoco 5 mg nasal spray, with a ceiling value of $1,126.10 and a firm fixed price contract type. This delivery order, which is expected to be completed by August 11, 2025, represents a non-set-aside, competitively awarded procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $1,129.62 to AmerisourceBergen Drug Corp for Valtoco 10 mg nasal sprays, with an ultimate completion date of September 3, 2025. This firm fixed-price contract, awarded on September 2, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. Valtoco is a naloxone nasal spray formulation used for...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Valtoco 10 mg nasal sprays, with a ceiling value of $1,129.62. This firm fixed-price delivery order represents a non-set-aside competitive award performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The contract is scheduled for completion by September 4, 2025, indicating a rapid fulfillment timeline typical of urgent medical supply needs within...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Valtoco 10 mg nasal sprays with a ceiling value of $1,441.57. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 15, 2025, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation and represents a child delivery order under a larger contract vehicle....
- The Defense Logistics Agency awarded a delivery order valued at $3,106.66 to AmerisourceBergen Drug Corp for Valtoco 10 mg nasal spray, with an ultimate completion date of September 15, 2025. This competitive award (no set-aside used) represents a firm fixed-price delivery order executed on September 12, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Valtoco is a naloxone nasal spray used for emergency treatment of opioid...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Valtoco 10 mg nasal sprays on September 11, 2025, with a ceiling value of $3,388.86. This firm fixed-price delivery order, which has no set-aside designation, represents a competitively awarded procurement supporting federal medical supply requirements. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 12, 2025....
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Valtoco 15 mg nasal spray with a ceiling value of $1,128.54. This is a firm fixed price, non-set-aside delivery order that will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 21, 2025. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Valtoco 10 mg nasal sprays under a firm fixed-price contract with a ceiling value of $1,543.14. The award was made on August 4, 2025, with an ultimate completion date of August 5, 2025. This is a non-set-aside, competitively awarded delivery order that will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Valtoco 10 mg nasal sprays valued at $1,355.52 on May 20, 2025, with an ultimate completion date of May 21, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FXANBDelivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Valtoco 20 mg nasal sprays, with a ceiling value of $5,854.54. The order is set to be completed by September 29, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside provisions and represents a continuation of AmerisourceBergen's extensive pharmaceutical supply role supporting federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), a $999,999,999 prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to military healthcare programs globally. Valtoco is a naloxone nasal spray utilized for emergency treatment of opioid overdose, reflecting the continued federal investment in accessible overdose reversal medications across the Defense Health Agency and related military healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.9k | 9/26/25 |